THE INFLUENCE OF AGE ON THE PHARMACOKINETICS OF THE ANTIEPILEPTIC AGENT OXCARBAZEPINE

被引:69
作者
VANHEININGEN, PNM
EVE, MD
OOSTERHUIS, B
JONKMAN, JHG
DEBRUIN, H
HULSMAN, JARJ
RICHENS, A
JENSEN, PK
机构
[1] PHARMA BIORES INT BV,ASSEN,NETHERLANDS
[2] CARDIFF CLIN TRIALS UNIT,CARDIFF,WALES
[3] CIBA GEIGY AG,CH-4002 BASEL,SWITZERLAND
[4] EPILEPSY CTR KEMPENHAEGHE,HEEZE,NETHERLANDS
关键词
D O I
10.1038/clpt.1991.158
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The disposition of oxcarbazepine was studied in 12 young and 12 elderly healthy male and 12 young and 12 elderly healthy female volunteers, with emphasis on the influence of age. Oxcarbazepine was administered as a single dose of either 300 mg (men) or 600 mg (women), followed by multiple-dose (300 mg) administration twice a day for 7 days (men) or 6 days (women). Semilogarithmic plasma concentration-time curves showed an increasing decline at decreasing concentrations. Accumulation of the pharmacologically active metabolite monohydroxycarbamazepine was found to be more than one would anticipate on the basis of linear and unchanged pharmacokinetics. Saturation did not seem to occur at the level of renal excretion. No apparent differences between male and female volunteers were observed. A significant higher maximum concentration, higher area under the curve parameters, and a lower elimination rate constant were observed in the elderly. These observations are in tine with a smaller renal clearance of monohydroxycarbamazepine in the elderly group. In a clinical situation, these age-related differences are not likely to have important implications. In general, treatment with oxcarbazepine was well tolerated.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 8 条
  • [1] AUGUSTEIJN R, 1990, ACTA NEUROL SCA S133, V82, P37
  • [2] FELDMANN KF, 1981, ADV EPILEPTOL, P89
  • [3] OXCARBAZEPINE (GP-47.680) - A POSSIBLE ALTERNATIVE TO CARBAMAZEPINE
    HOUTKOOPER, MA
    LAMMERTSMA, A
    MEYER, JWA
    GOEDHART, DM
    MEINARDI, H
    VANOORSCHOT, CAEH
    BLOM, GF
    HOPPENER, RJEA
    HULSMAN, JARJ
    [J]. EPILEPSIA, 1987, 28 (06) : 693 - 698
  • [4] KRAMER G, 1985, EPILEPSIE 84, P379
  • [5] PHARMACOKINETICS OF 10-OH-CARBAZEPINE, THE MAIN METABOLITE OF THE ANTI-EPILEPTIC OXCARBAZEPINE, FROM SERUM AND SALIVA CONCENTRATIONS
    KRISTENSEN, O
    KLITGAARD, NA
    JONSSON, B
    SINDRUP, S
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1983, 68 (03): : 145 - 150
  • [6] REINIKAINEN K, 1984, ACTA NEUROL SCAND, V69, P89
  • [7] THE METABOLISM OF OXCARBAZEPINE-C-14 IN MAN
    SCHUTZ, H
    FELDMANN, KF
    FAIGLE, JW
    KRIEMLER, HP
    WINKLER, T
    [J]. XENOBIOTICA, 1986, 16 (08) : 769 - 778
  • [8] DISPOSITION OF THE ANTI-EPILEPTIC OXCARBAZEPINE AND ITS METABOLITES IN HEALTHY-VOLUNTEERS
    THEISOHN, M
    HEIMANN, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (06) : 545 - 551